Eligibility Criteria | Clinical stage I, II or III (M0; N0-2; T1-3) pleural mesothelioma |
Performance status 0 to 1on the ECOGa performance status schedule | |
No previous surgical resection of mesothelioma | |
No previous radiation therapy | |
Estimated life expectancy of at least 12 weeks | |
Adequate cardiac function | |
Must be judged suitable to the therapy by medical oncologist and thoracic surgeon. | |
Pulmonary function tests: FEV1b >0.8, DLCOc >35% of predicted postoperative FEV1 (ppoFEV1) | |
ABGd Predicted postoperative pCO2 <50. | |
Adequate bone marrow reserve: | |
· absolute neutrophil (segmented and bands) count (ANC) ≥1.5 × 109/L, | |
· Platelets ≥100 × 109/L, and hemoglobin ≥9 g/dL. | |
Hepatic: bilirubin ≤1.5 times the upper limit of normal (× ULN), alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤3.0 × ULN. | |
Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. | |
Geographical condition must not hamper the compliance with the study protocol and follow-up schedule. |